Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

about

Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management.Effect of Regulatory Network of Exosomes and microRNAs on Neurodegenerative Diseases

P2860

Q52583507-6FBAFE48-1D69-48C7-AAA1-FC0D4811102F Q58714289-C2487794-6B83-4C8F-9194-69B7B7D928A2

P2860

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

Item

http://www.wikidata.org/entity/Q38658203

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

@en

type

Item

label

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

@en

prefLabel

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

@en

P1476

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

@en

P2093

Juan-Juan Du

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

Adenosine A2A receptors and basal ganglia physiology

Histamine and the striatum

Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Staging of brain pathology related to sporadic Parkinson's disease

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation.

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

P304

1856-1866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.4103/0366-6999.211555

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Sheng-Di Chen

P5008

ScienceSource

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28748860

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5547839

http://www.w3.org/2001/XMLSchema#string

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

about

P2860

P2860

Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932